Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.
Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The Company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how.